Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study
Fu R, Sun K, Wang X, Liu B, Wang T, Morze J, Nawrocki S, An L, Zhang S, Li L, Wang S, Chen R, Sun K, Han B, Lin H, Wang H, Liu D, Wang Y, Li Y, Zhang Q, Mu H, Geng Q, Sun F, Zhao H, Zhang X, Lu L, Mei D, Zeng H, Wei W. Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study. The Lancet Regional Health - Western Pacific 2023, 37: 100799. PMID: 37693879, PMCID: PMC10485681, DOI: 10.1016/j.lanwpc.2023.100799.Peer-Reviewed Original ResearchExcess hazard ratioStage-specific survivalCancer patientsCancer survivalRelative survivalCancer typesIndividual cancersEnd Results (SEER) databasePopulation-based studyFemale breast cancerLung cancer patientsCancer registry dataCancer early detectionMedical SciencesHazard ratioOverall prognosisSurvival disparitiesResults databaseCancer HospitalCancer RegistryCervical cancerPoor prognosisVital statusColorectal cancerCancer careDisparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategies